Research programme: alpha-emitting monoclonal antibody radiopharmaceuticals - Actinium Pharmaceuticals

Drug Profile

Research programme: alpha-emitting monoclonal antibody radiopharmaceuticals - Actinium Pharmaceuticals

Alternative Names: AA-A225; Ac-225 labeled anti-A33 monoclonal antibody; Ac-225-labeled anti-CD45 monoclonal antibody; Ac-255 labeled AA; Actimab-B; Actimab-C; Actimab-P; anti-A33 monoclonal antibody Ac-225; anti-CD45 monoclonal antibody BC8-Ac-225

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Fred Hutchinson Cancer Research Center
  • Developer Actinium Pharmaceuticals; Fred Hutchinson Cancer Research Center; Memorial Sloan-Kettering Cancer Center
  • Class Immunoconjugates; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Angiogenesis inhibitors; CD45 antigen inhibitors; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haematological malignancies
  • No development reported Acute myeloid leukaemia; Cancer; Colorectal cancer; Prostate cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in USA (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Colorectal-cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top